ImmunityBio's ANKTIVA Gets NCCN Nod for Broader Bladder Cancer Use—But FDA Approval Still Looms

The recent NCCN guideline update is a clear commercial win, but it's a win that was already priced in. The market has been buying the rumor for months. The stock's year-to-date surge of over 315% reflects a powerful expectation that ImmunityBio's ANKTIVA would gain broader clinical recognition. This update delivers that, but it does so in a way that highlights the gap between today's reality and tomorrow's potential.

The specific change is significant. The NCCN has expanded its 2026 guidelines to include ANKTIVA plus BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer who have papillary-only disease. This is a new patient population beyond the earlier recommendation for those with carcinoma in situ (CIS). The update is a major endorsement from the medical community, positioning ANKTIVA alongside other bladder-sparing options like chemotherapy. Yet, the key detail is that this new use is not currently included in the U.S. FDA-approved label. The recommendation carries a Category 2A designation, which means it's based on uniform expert consensus but on lower-level evidence. This creates a clear regulatory gap: the guidelines say it's a good option, but the FDA hasn't formally approved it.

For investors, the setup is classic expectation arbitrage. The NCCN update confirms the commercial narrative that ANKTIVA is becoming a standard-of-care option for a larger patient pool. That was the whisper number driving the stock's massive rally. The update itself is a beat on that expectation. The real question now is whether the stock can climb further on the next beat—the FDA approval for this new indication. Until that happens, the stock is likely to trade on the strength of the guidance itself, which, while positive, is not yet a regulatory stamp of approval.

Commercial Reality vs. Future Potential

The numbers tell a clear story of accelerating commercial momentum. For the quarter ending December 31, 2025, ANKTIVA's preliminary net product revenue hit $38.3 million. That represents a solid 20% jump from the prior quarter and a staggering 431% increase year-over-year. The full-year 2025 revenue is on track to be roughly $113 million, a surge of about 700% from the previous year. This is the reality the market is pricing in today: a therapy that is rapidly gaining traction in its approved patient population.

Yet, the future potential implied by the expanded NCCN guidelines is a different beast. The current U.S. label covers patients with BCG-unresponsive non-muscle invasive bladder cancer who have carcinoma in situ (CIS) with or without papillary disease. The new NCCN recommendation, however, explicitly includes patients with papillary-only disease. This is a significant expansion of the potential patient pool. The guidelines now position ANKTIVA alongside other bladder-sparing options, a clear endorsement that could drive adoption. But here's the critical gap: this new use has not yet been approved by the FDA. The market is looking ahead to a regulatory approval that hasn't happened, creating a classic expectation gap.

For now, ANKTIVA remains the company's entire near-term revenue driver. Other pipeline therapies, like the autologous M-ceNK cell therapy, are still in development. The recent completion of manufacturing engineering programs for M-ceNK is a positive step, but it's years away from commercial impact. The stock's recent choppiness—giving up early gains after the NCCN update—shows that investors are weighing this reality. The commercial beat is clear, but the next major catalyst is the FDA approval for the expanded indication. Until that happens, the stock's path will be dictated by the tension between today's strong sales growth and tomorrow's unapproved potential.

Valuation and Forward Catalysts

The market is now paying a steep price for ImmunityBio's growth story. With a market cap of roughly $8.8 billion, the stock trades at a valuation that assumes a long, smooth path to commercial dominance. The recent 1-year target estimate of $14.80 implies significant upside from current levels, but that target is a bet on a future that remains unproven by regulation. The critical question is whether the current price adequately discounts the multi-year timeline for the next major catalyst.

That catalyst is an FDA label expansion request based on the NCCN guidelines. The company has the data and the endorsement, but translating a Category 2A guideline recommendation into a formal FDA approval is a process that can take years. The guidelines are a powerful commercial tool, shaping which therapies doctors and insurers consider standard of care. Yet, without an approved label, ANKTIVA's use for papillary-only disease remains off-label, creating a regulatory gap that the market must bridge with patience. The stock's recent choppiness shows investors are weighing this reality. The valuation is high for a therapy still in the early stages of its commercial ramp, even as it surges.

The company's recent earnings history provides a mixed signal. ImmunityBio has consistently beaten expectations, with a 25% EPS surprise last quarter and a track record of topping revenue estimates. This execution is priced in and has fueled the rally. However, these are still losses on a per-share basis, and the company's path to profitability depends entirely on ANKTIVA's expansion. The market is now looking past the beat-and-raise narrative of the last few quarters to the next hurdle: regulatory approval. Until the FDA acts, the stock's valuation will remain a function of how much investors are willing to pay for a promise, not a guarantee.